Immunocore Holdings (IMCR) News & Sentiment

Immunocore presents initial multiple ascending dose data for HIV functional cure candidate in an oral presentation at CROI 2025

(OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & GAITHERSBURG, Md., US, 03 March 2025) Immunocore Holdings plc (Nasdaq: IMCR) (“Immunocore” or the “Company”), a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases and autoimmune diseases, today announced that management will participate in the following investor conferences in March.

Immunocore Holdings focuses on immunotherapy for oncology, with tebentafusp approved for metastatic uveal melanoma and brenetafusp in advanced trials. IMCR's strong balance sheet, with over $800 million in liquid assets, positions them well for future R&D or even a potential acquisition. Growth of tebentafusp sales has slowed, increasing reliance on new projects like brenetafusp, which carries inherent biotech industry risks.

Immunocore Holdings plc (NASDAQ:IMCR ) Q4 2024 Earnings Conference Call February 26, 2024 8:00 AM ET Company Participants Clayton Robertson - Head, IR Bahija Jallal - CEO Travis Coy - CFO and Head, Corporate Development Ralph Torbay - Head, Commercial David Berman - Head, R&D Conference Call Participants Michael Yee - Jefferies Jessica Fye - JPMorgan Tyler Van Buren - TD Cowen Eric Schmidt - Cantor Fitzgerald Justin Zelin - BTIG Jonathan Chang - Leerink Partners Ethan Markowski - Needham & Company Peter Lawson - Barclays Patrick Trucchio - H.C. Wainwright Rajan Sharma - Goldman Sachs David Dai - UBS Jeff Jones - Oppenheimer Operator Greetings and welcome to the Immunocore Conference Call and Webcast.

KIMMTRAK (tebentafusp) Q4 net sales of $84.1 million and $310.0 million for full year 2024; continued growth expected in 2025

(OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & GAITHERSBURG, Md., US, 19 February 2025) Immunocore Holdings plc (Nasdaq: IMCR) (“Immunocore” or the “Company”), a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases and autoimmune diseases, today announced that it will report financial results for the fourth quarter and year ended December 31, 2024 on Wednesday, February 26, 2025.

IMCR's fourth-quarter 2024 earnings are likely to have gained from higher sales of its sole marketed product, Kimmtrak.

The average of price targets set by Wall Street analysts indicates a potential upside of 113.1% in Immunocore (IMCR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Reaching more mUM patients globally with KIMMTRAK (tebentafusp) in 2025 through additional launches and increased community penetration